Indications with the highest fold change between tumor and non-transformed tissue for EGFR included thymoma (THYM) (>600-fold change), GBM (>20-fold change) and LGG (≥5-fold change) (Figure 1C,E), followed by KIRC, stomach adenocarcinoma (STAD), lung squamous cell carcinoma (LUSC), ESCA, pancreatic adenocarcinoma (PAAD), HNSC and sarcoma (SARC) (all ≥1.5-fold change) (Figure 1C). This evidence concerns the gene EGFR and glioblastoma.